Insights into new mechanisms and models of cancer stem cell multidrug resistance

Area of Science:

• Oncology
• Cancer Biology
• Molecular Medicine

Background:

• Cancer progression, metastasis, and therapy resistance are driven by genetic alterations, clonal evolution, and the tumor microenvironment.
• Phenotypic heterogeneity and plasticity of cancer cells contribute to tumor progression and treatment resistance.
• Multidrug resistance (MDR) and cancer relapse remain significant challenges in oncology, leading to poor patient outcomes.

Purpose of the Study:

• To provide an integrated overview of MDR mechanisms in cancer stem cells (CSCs).
• To propose a novel model for tumor evolution during chemotherapy.
• To identify potential therapeutic strategies targeting CSC resistance.

Main Methods:

• Review and integration of existing literature on CSCs and MDR.
• Analysis of proposed CSC resistance mechanisms, including drug efflux, DNA damage response, apoptosis evasion, and metabolic alterations.
• Conceptual modeling of tumor evolution under chemotherapeutic pressure.

Main Results:

• CSCs are implicated as a major cause of cancer relapse, metastasis, and resistance to various therapies (radiotherapy, chemotherapy, hormone therapy).
• Multiple CSC resistance mechanisms exist, including ABC transporter-mediated drug efflux, enhanced DNA damage response (DDR), apoptosis evasion, and metabolic reprogramming.
• Current targeted therapies against CSC mechanisms show only partial efficacy, suggesting additional underlying causes for CSC resilience.

Conclusions:

• Targeting specific CSC resistance pathways may offer new therapeutic avenues.
• A comprehensive understanding of CSC MDR mechanisms is essential for improving cancer treatment outcomes.
• Novel therapeutic strategies targeting CSCs are needed to overcome treatment resistance and prevent relapse.